Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 12/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.51 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.48 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.45 |
| ▸ | HK1 | P19367 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26356913 | 1.00 | KEAP1 (0.51) | KEAP1NFE2L2EP300KAT2BKAT8 | |
| SCHEMBL29539804 | 0.94 | KMT2A (0.47) | KEAP1NFE2L2EP300KAT2BKAT8 | |
| SCHEMBL22922455 | 0.94 | KMT2A (0.47) | KEAP1NFE2L2EP300KAT2BKAT8 | |
| SCHEMBL29539829 | 0.92 | KEAP1 (0.50) | KEAP1NFE2L2HKDC1HK1MCL1 | |
| SCHEMBL22922652 | 0.92 | KEAP1 (0.50) | KEAP1NFE2L2HKDC1HK1MCL1 | |
| SCHEMBL24299708 | 0.92 | HKDC1 (0.47) | KEAP1NFE2L2HKDC1MCL1KCNA5 | |
| SCHEMBL29539562 | 0.92 | HKDC1 (0.47) | KEAP1NFE2L2HKDC1MCL1KCNA5 | |
| SCHEMBL26356935 | 0.92 | KEAP1 (0.48) | KEAP1NFE2L2EP300KAT2BKAT8 | |
| SCHEMBL29539625 | 0.92 | KEAP1 (0.48) | KEAP1NFE2L2EP300KAT2BKAT8 | |
| SCHEMBL26356901 | 0.91 | KEAP1 (0.49) | KEAP1NFE2L2EP300KAT2BKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3978471-B1 | NAPHTHALENESULFONAMIDE COMPOUND, PREPARATION METHOD, AND APPLICATION | UNIV CHINA PHARMA (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-20220251035-A1 | NAPHTHALENESULFONAMIDE COMPOUND, PREPARATION METHOD, AND APPLICATION | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2022-08-11 | — | — | US | disclosed |
| EP-3978471-A1 | NAPHTHALENESULFONAMIDE COMPOUND, PREPARATION METHOD, AND APPLICATION | China Pharmaceutical University (CN) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251035-A1 | NAPHTHALENESULFONAMIDE COMPOUND, PREPARATION METHOD, AND APPLICATION | NFE2L2, KEAP1, NFE2 | KEAP1 2/4885NFE2L2 1/4885EP300 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.